ClinicalTrialsFinder

Primary Hyperoxaluria Type 1 Clinical Trials in New York, New York

1 recruitingNew York, New York

Showing 1–1 of 1 trials

Recruiting
Phase 2

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

End Stage Renal DiseasePrimary Hyperoxaluria Type 1
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company28 enrolled18 locationsNCT04580420